Market Access News
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The August 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: 7 negotiations were completed, while none were closed for a total of 235 completed/closed negotiations; 9 new drug products have initiated pCPA negotiations, for a total of 48 active negotiations; No new drug products were added to the “No pCPA Negotiations”…
On September 13th, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued details on a new CADTH and Institut national d’excellence en santé et en services sociaux (INESSS) pilot project to jointly engage with clinical specialists. According to CADTH’s communication, the objectives of the pilot project are to: Strengthen the current pharmaceutical review processes used by CADTH and INESSS with respect to engagement with Canadian clinical specialists.…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The July 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: 9 negotiations were completed, while none were closed for a total of 228 completed/closed negotiations; 8 new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; No new drug products were added to the “No pCPA Negotiations”…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The June 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Three negotiations were completed, while one negotiation was closed for a total of 193 completed negotiations and 26 closed negotiations; Eight new drug products have initiated pCPA negotiations, for a total of 47 active negotiations; No new drug products were added…
pCPA Brand Process Guidelines Webinar On Friday, June 22nd, 2018 the pan-Canadian Pharmaceutical Alliance Office (pCPAO) hosted an industry consultation session via webinar, on the newly completed pCPA Brand Process Guidelines (“the Guidelines”). The objective of this webinar was to: introduce the Guidelines and supportive documents developed by the pCPA; and invite industry’s initial feedback. This edition of MORSE Signals provides an overview of the webinar and outlines key…
Optimizing Alberta’s Health Data: Innovative Collaboration in Real World Evidence (RWE) Generation Alberta has long been known for its leadership in the energy sector and for its entrepreneurial spirit reputation for being a trail blazer across the political spectrum. Historically, Alberta’s economic engine has been its natural resources. The other major Alberta resource that is less well known is health data. Much like its natural resources, data needs to…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The May 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Three negotiations were completed, while three more were closed for a total of 215 completed/closed negotiations; Three new drug products have initiated pCPA negotiations, for a total of 42 active negotiations; One new drug product was added to the “No pCPA…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The April 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Seven new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; One negotiation was completed (none closed), for a total of 208 joint completed/closed negotiations; and No new drug products were added to the “No pCPA Negotiations”…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The March 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Four new drug products have initiated pCPA negotiations, for a total of 40 active negotiations; Two negotiations have been completed (none closed), for a total of 207 joint completed/closed negotiations; and One new drug product was added to the…
MORSE Consulting’s Managing Principal, Sherry O’Quinn, and Principal Consultant, Brad Alyward, are proud to participate in this year’s CADTH Symposium taking place from April 15-17, 2018 in Halifax, Nova Scotia. Further details on MORSE, and its strategic partner’s (Cornerstone Research Group) participation can be found below. April 16, 2018 15:15-16:30 ADT Sherry O’Quinn moderates a panel on oncology drugs with Alex Chambers (CADTH), Scott Gavura (CCO), Elena Lungu…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The February 28, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Seven new drug products have initiated pCPA negotiations, for a total of 39 active negotiations; Five negotiations have been completed/closed, for a total of 205 joint completed/closed negotiations; and No new drug products were added to the “No pCPA…
A Comparison of Proposed INESSS and Current CADTH Evaluation Fees On February 21, 2018, the Quebec government released draft regulations (Gazette Officielle du Québec) that outline fees payable to Institut national d'excellence en santé et en services sociaux (INESSS) for the scientific evaluation of a drug or stable blood product. The fees are expected to vary based on the type of dossier submitted for scientific review with INESSS determining…
pCPA Monthly Trends & Insights – January 2018 The January 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Two new drug products have initiated pCPA negotiations, for a total of 36 active negotiations; Four negotiations have been completed/closed, for a total of 200 joint completed/closed negotiations; and No new drug products were added to the “No…
Toronto, February 7, 2018: Cornerstone Research Group and MORSE Consulting are pleased to announce the creation of a strategic partnership between our two organizations. This strategic partnership will simplify the logistical process for our clients utilizing our combined services when shepherding a product from reimbursement strategy, to CADTH submission and finally to pCPA negotiations. Together the collaboration between Cornerstone and MORSE offers clients a breadth of reimbursement consulting services…
MORSE Consulting has prepared a Year in Review infographic to highlight some key metrics surrounding the pCPA’s activities in 2017. This analysis highlights completed negotiations broken down in a number of different ways as well as several initiation and negotiation timing measures. MORSE concludes the analysis with our overall perspective on pCPA’s activities over the past year. Click here to view full-size infographic Click here to view full-size…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
Browse our Market Access News section - Page 8 of 11 - MORSE Consulting Inc.
